Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.

Johänning J, Kröner P, Thomas M, Zanger UM, Nörenberg A, Eichelbaum M, Schwab M, Brauch H, Schroth W, Mürdter TE.

Arch Toxicol. 2018 Mar;92(3):1099-1112. doi: 10.1007/s00204-017-2147-y. Epub 2017 Dec 28.

2.

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.

Schroth W, Winter S, Mürdter T, Schaeffeler E, Eccles D, Eccles B, Chowbay B, Khor CC, Tfayli A, Zgheib NK, Eichelbaum M, Schwab M, Brauch H.

Front Pharmacol. 2017 Aug 24;8:582. doi: 10.3389/fphar.2017.00582. eCollection 2017.

3.

Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods.

Häberle L, Hein A, Rübner M, Schneider M, Ekici AB, Gass P, Hartmann A, Schulz-Wendtland R, Beckmann MW, Lo WY, Schroth W, Brauch H, Fasching PA, Wunderle M.

Geburtshilfe Frauenheilkd. 2017 Jun;77(6):667-678. doi: 10.1055/s-0043-111602. Epub 2017 Jun 28.

4.

The Educational Climate Inventory: Measuring Students' Perceptions of the Preclerkship and Clerkship Settings.

Krupat E, Borges NJ, Brower RD, Haidet PM, Schroth WS, Fleenor TJ Jr, Uijtdehaage S.

Acad Med. 2017 Dec;92(12):1757-1764. doi: 10.1097/ACM.0000000000001730.

PMID:
28562457
5.

SK4 channels modulate Ca2+ signalling and cell cycle progression in murine breast cancer.

Steudel FA, Mohr CJ, Stegen B, Nguyen HY, Barnert A, Steinle M, Beer-Hammer S, Koch P, Lo WY, Schroth W, Hoppe R, Brauch H, Ruth P, Huber SM, Lukowski R.

Mol Oncol. 2017 Sep;11(9):1172-1188. doi: 10.1002/1878-0261.12087. Epub 2017 Jun 26.

6.

Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.

Sutiman N, Lim JSL, Muerdter TE, Singh O, Cheung YB, Ng RCH, Yap YS, Wong NS, Ang PCS, Dent R, Schroth W, Schwab M, Khor CC, Chowbay B.

Clin Pharmacokinet. 2016 Oct;55(10):1239-1250. doi: 10.1007/s40262-016-0402-7.

PMID:
27098059
7.

Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.

Lim JS, Sutiman N, Muerdter TE, Singh O, Cheung YB, Ng RC, Yap YS, Wong NS, Ang PC, Dent R, Schroth W, Schwab M, Chowbay B.

Br J Clin Pharmacol. 2016 Jun;81(6):1142-52. doi: 10.1111/bcp.12886. Epub 2016 Mar 8.

8.

Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.

Schroth W, Winter S, Büttner F, Goletz S, Faißt S, Brinkmann F, Saladores P, Heidemann E, Ott G, Gerteis A, Alscher MD, Dippon J, Schwab M, Brauch H, Fritz P.

Breast Cancer Res Treat. 2016 Jan;155(1):85-97. doi: 10.1007/s10549-015-3651-5. Epub 2015 Dec 9.

PMID:
26650824
9.

Comparative Analysis and Functional Characterization of HC-AFW1 Hepatocarcinoma Cells: Cytochrome P450 Expression and Induction by Nuclear Receptor Agonists.

Braeuning A, Thomas M, Hofmann U, Vetter S, Zeller E, Petzuch B, Johänning J, Schroth W, Weiss TS, Zanger UM, Schwarz M.

Drug Metab Dispos. 2015 Nov;43(11):1781-7. doi: 10.1124/dmd.115.064667. Epub 2015 Aug 26.

10.

Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS.

Johänning J, Heinkele G, Precht JC, Brauch H, Eichelbaum M, Schwab M, Schroth W, Mürdter TE.

Anal Bioanal Chem. 2015 Sep;407(24):7497-502. doi: 10.1007/s00216-015-8907-8. Epub 2015 Jul 25.

PMID:
26206706
11.

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H.

Pharmacogenomics J. 2015 Feb;15(1):84-94. doi: 10.1038/tpj.2014.34. Epub 2014 Aug 5.

12.

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.

Li J, Czene K, Brauch H, Schroth W, Saladores P, Li Y, Humphreys K, Hall P.

Breast Cancer Res. 2013;15(5):R93.

13.

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.

14.

Reply to A.-S. Dieudonné et al and J.M. Rae et al.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jul 20;31(21):2755-6. No abstract available.

PMID:
24040664
15.

Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.

Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo WY, Schroth W, Brauch H.

Eur J Cancer. 2013 Nov;49(17):3598-608. doi: 10.1016/j.ejca.2013.07.145. Epub 2013 Aug 19.

PMID:
23968733
16.

The letrozole phase 1 metabolite carbinol as a novel probe drug for UGT2B7.

Precht JC, Schroth W, Klein K, Brauch H, Krynetskiy E, Schwab M, Mürdter TE.

Drug Metab Dispos. 2013 Nov;41(11):1906-13. doi: 10.1124/dmd.113.053405. Epub 2013 Aug 21.

17.

Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.

Saladores PH, Precht JC, Schroth W, Brauch H, Schwab M.

Expert Rev Mol Diagn. 2013 May;13(4):349-65. doi: 10.1586/erm.13.26. Review.

PMID:
23638818
18.

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22. No abstract available.

19.

Perspective: deconstructing integration: a framework for the rational application of integration as a guiding curricular strategy.

Goldman E, Schroth WS.

Acad Med. 2012 Jun;87(6):729-34. doi: 10.1097/ACM.0b013e318253cad4.

PMID:
22534596
20.

Effecting curricular change through comprehensive course assessment: using structure and process to change outcomes.

Goldman EF, Swayze SS, Swinehart SE, Schroth WS.

Acad Med. 2012 Mar;87(3):300-7. doi: 10.1097/ACM.0b013e318244739c.

PMID:
22373621
21.

Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.

Mürdter TE, Kerb R, Turpeinen M, Schroth W, Ganchev B, Böhmer GM, Igel S, Schaeffeler E, Zanger U, Brauch H, Schwab M.

Hum Mol Genet. 2012 Mar 1;21(5):1145-54. doi: 10.1093/hmg/ddr543. Epub 2011 Nov 22.

PMID:
22108178
22.

CYP2D6 and tamoxifen: awaiting the denouement.

Brauch HB, Schroth W, Ingle JN, Goetz MP.

J Clin Oncol. 2011 Dec 1;29(34):4589-90; author reply 4590-1. doi: 10.1200/JCO.2011.38.8611. Epub 2011 Oct 31. No abstract available.

PMID:
22042960
23.

Student affairs officers should oversee preparation of the medical student performance evaluation.

Schroth WS, Barrier PA, Garrity M, Kavan MG.

Acad Med. 2011 Nov;86(11):1336. doi: 10.1097/ACM.0b013e31823007f9. No abstract available.

PMID:
22030635
24.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.

25.

Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.

Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H.

Clin Pharmacol Ther. 2011 May;89(5):708-17. doi: 10.1038/clpt.2011.27. Epub 2011 Mar 30. Erratum in: Clin Pharmacol Ther. 2012 Jun;91(6):1087.

PMID:
21451508
26.

Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression.

Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W.

Clin Chem. 2010 Dec;56(12):1845-53. doi: 10.1373/clinchem.2010.151233. Epub 2010 Oct 14.

27.

The George Washington University School of Medicine and Health Sciences.

Schroth WS.

Acad Med. 2010 Sep;85(9 Suppl):S127-30. doi: 10.1097/ACM.0b013e3181e86ce5. No abstract available.

PMID:
20736530
28.

ABCC2 and clinical outcome of tamoxifen therapy.

Lang T, Schroth W, Brauch H, Schwab M.

J Clin Oncol. 2010 Sep 1;28(25):e448; author reply e449. doi: 10.1200/JCO.2010.29.6665. Epub 2010 Jul 12. No abstract available.

PMID:
20625134
29.

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.

Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M, Brauch H.

Clin Cancer Res. 2010 Sep 1;16(17):4468-77. doi: 10.1158/1078-0432.CCR-10-0478. Epub 2010 Jun 1.

30.

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H.

JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420.

31.

Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.

Braun N, Fritz P, Rieth A, Schroth W, Kimmel M, Biegger D, Zakim D, Alscher MD.

J Rheumatol. 2009 Oct;36(10):2269-76. doi: 10.3899/jrheum.090075. Epub 2009 Aug 14.

PMID:
19684157
32.

Bilateral renal-cell carcinoma associated with an acquired VHL mutation and long-term trichloroethylene exposure.

Wells GM, Schroth W, Brauch H, Ross EA.

Clin Nephrol. 2009 Jun;71(6):708-13.

PMID:
19473641
33.

Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE.

BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364.

34.

A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.

Rokavec M, Schroth W, Amaral SM, Fritz P, Antoniadou L, Glavac D, Simon W, Schwab M, Eichelbaum M, Brauch H.

Cancer Res. 2008 Dec 1;68(23):9799-808. doi: 10.1158/0008-5472.CAN-08-0247.

35.

The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.

Amaral S, Schroth W, Kugler S, Fritz P, Simon W, Brauch H.

Breast Cancer Res Treat. 2009 Nov;118(2):323-31. doi: 10.1007/s10549-008-0241-9. Epub 2008 Nov 15.

PMID:
19011961
36.

Estrogen-mediated downregulation of CD24 in breast cancer cells.

Kaipparettu BA, Malik S, Konduri SD, Liu W, Rokavec M, van der Kuip H, Hoppe R, Hammerich-Hille S, Fritz P, Schroth W, Abele I, Das GM, Oesterreich S, Brauch H.

Int J Cancer. 2008 Jul 1;123(1):66-72. doi: 10.1002/ijc.23480.

37.

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.

Brauch H, Schroth W, Eichelbaum M, Schwab M, Harbeck N; in cooperation with the AGO TRAFO Comission.

Breast Care (Basel). 2008;3(1):43-50. Epub 2008 Feb 22.

38.

A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk.

Rokavec M, Justenhoven C, Schroth W, Istrate MA, Haas S, Fischer HP, Vollmert C, Illig T, Hamann U, Ko YD, Glavac D, Brauch H.

Clin Cancer Res. 2007 Dec 15;13(24):7506-14.

39.

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H.

J Clin Oncol. 2007 Nov 20;25(33):5187-93.

PMID:
18024866
40.

Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.

Jaremko M, Justenhoven C, Schroth W, Abraham BK, Fritz P, Vollmert C, Illig T, Simon W, Schwab M, Brauch H.

Pharmacogenet Genomics. 2007 Jul;17(7):529-38.

PMID:
17558308
41.

Molecular structures and electronic transitions of 3,6-diphenyl-1,2-dithiin and its radical cation: a spectroelectrochemical and DFT study.

Hennig H, Schumer F, Reinhold J, Kaden H, Oelssner W, Schroth W, Spitzner R, Hartl F.

J Phys Chem A. 2006 Feb 9;110(5):2039-44.

PMID:
16451040
42.

Molecular biomarkers and adaptation to environmental stress in moon jelly (Aurelia spp.).

Schroth W, Ender A, Schierwater B.

Mar Biotechnol (NY). 2005 Sep-Oct;7(5):449-61. Epub 2005 Jun 4.

PMID:
15976937
43.

MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET).

Jaremko M, Justenhoven C, Abraham BK, Schroth W, Fritz P, Brod S, Vollmert C, Illig T, Brauch H.

Hum Mutat. 2005 Mar;25(3):232-8.

PMID:
15706592
44.

Randomized controlled trial of education and feedback for implementation of guidelines for acute low back pain.

Schectman JM, Schroth WS, Verme D, Voss JD.

J Gen Intern Med. 2003 Oct;18(10):773-80.

45.

Speciation and phylogeography in the cosmopolitan marine moon jelly, Aurelia sp.

Schroth W, Jarms G, Streit B, Schierwater B.

BMC Evol Biol. 2002;2:1. Epub 2002 Jan 2.

46.

The George Washington University School of Medicine and Health Sciences.

Schroth WS.

Acad Med. 2000 Sep;75(9 Suppl):S50-2. No abstract available.

PMID:
10995638
47.

(3R*,3'R*)-1,1'-dimethyl-3,3'-biindoline-2,2'-dithione

Baumeister U, Hartung H, Spitzner R, Felicetti M, Schroth W.

Acta Crystallogr C. 2000 Jul;56 (Pt 7):830-1. No abstract available.

PMID:
10935096
48.

Molecular resolution of marine turtle stock composition in fishery bycatch: a case study in the Mediterranean.

Laurent L, Casale P, Bradai MN, Godley BJ, Gerosa G, Broderick AC, Schroth W, Schierwater B, Levy AM, Freggi D, Abd el-Mawla EM, Hadoud DA, Gomati HE, Domingo M, Hadjichristophorou M, Kornaraky L, Demirayak F, Gautier C.

Mol Ecol. 1998 Nov;7(11):1529-42.

PMID:
9819906
49.

Development and multicenter evaluation of Multistation Clinical Teaching Scenarios on immunization: the ATPM-CDC Teaching Immunization for Medical Education (TIME) Project.

Zimmerman RK, Janosky JE, Wald ER, Ruben FL, Schroth WS, Mieczkowski TA, Ahwesh ER, Kanter SL.

Am J Prev Med. 1997 Mar-Apr;13(2):78-83.

PMID:
9088442
50.

The effect of education and drug samples on antihistamine prescribing costs in an HMO.

Schectman JM, Schroth WS, Elinsky EG, Ott JE.

HMO Pract. 1996 Sep;10(3):119-22.

PMID:
10160286

Supplemental Content

Loading ...
Support Center